Your session is about to expire
← Back to Search
Steroid Synthesis Inhibitor
DST-2970 (Abiraterone) for Prostate Cancer
Phase 1
Waitlist Available
Research Sponsored by DisperSol Technologies, LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 12-18 months
Awards & highlights
No Placebo-Only Group
Summary
This trial is a Phase I study to test the safety and effectiveness of a new drug, DST-2970, in prostate cancer patients who have developed resistance to abiraterone acetate, a standard hormone therapy. The study will include a dose escalation phase followed by a dose expansion phase.
Eligible Conditions
- Prostate Cancer
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 12-18 months
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~12-18 months
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Secondary study objectives
Body Weight Changes
Change in Tumor Size
Duration of response (DoR)
+3 moreOther study objectives
Exploration of potential biomarkers
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Prostate CancerExperimental Treatment3 Interventions
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Abiraterone Acetate
2015
Completed Phase 4
~1880
Find a Location
Who is running the clinical trial?
DisperSol Technologies, LLCLead Sponsor
1 Previous Clinical Trials
25 Total Patients Enrolled
Translational Drug DevelopmentOTHER
18 Previous Clinical Trials
978 Total Patients Enrolled
1 Trials studying Prostate Cancer
23 Patients Enrolled for Prostate Cancer
Share this study with friends
Copy Link
Messenger